trending Market Intelligence /marketintelligence/en/news-insights/trending/kGEYUU2ss7QifMKFuXc_FQ2 content esgSubNav
In This List

Edwards Lifesciences profit beats consensus by 15.6% in Q3


Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection


Japan M&A By the Numbers: Q4 2023


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Edwards Lifesciences profit beats consensus by 15.6% in Q3

Edwards Lifesciences Corp. said its third-quarter adjusted earnings amounted to $1.41 per share, compared with the S&P Global Market Intelligence consensus normalized EPS estimate of $1.22 per share.

EPS climbed 31.8% year over year from $1.07.

Adjusted earnings totaled $299.2 million, a gain of 31.2% from $228.1 million in the year-earlier period. Net sales grew 20.7% year over year to $1.09 billion from $906.6 million.

GAAP net income increased 21.6% year over year to $274.7 million, or $1.30 per share, from $225.9 million, or $1.06 per share.

The Irvine, Calif.-based medical-device maker forecasts adjusted EPS in the range of $5.50 to $5.65 for the full year 2019, an increase from previous guidance in the range of $5.20 to $5.40.

Edwards Lifesciences expects total sales in the range of $4 billion to $4.3 billion for the full year.